Other Psychiatric Disorders – Pipeline Review, H2 2012

Other Psychiatric Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Other Psychiatric Disorders - Pipeline Review, H2 2012', provides an overview of the Other Psychiatric Disorders therapeutic pipeline. This report provides information on the therapeutic development for Other Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Psychiatric Disorders. 'Other Psychiatric Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Psychiatric Disorders.
- A review of the Other Psychiatric Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Psychiatric Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Psychiatric Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Psychiatric Disorders pipeline depth and focus of Other Psychiatric Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Other Psychiatric Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Other Psychiatric Disorders 8
Other Psychiatric Disorders Therapeutics under Development by Companies 10
Other Psychiatric Disorders Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Other Psychiatric Disorders Therapeutics – Products under Development by Companies 16
Other Psychiatric Disorders Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Other Psychiatric Disorders Therapeutics Development 18
Corcept Therapeutics Incorporated 18
Supernus Pharmaceuticals, Inc. 19
Other Psychiatric Disorders – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
selective GR-II receptor antagonist - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Oxytocin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Methylphenidate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Nortriptyline + Transdermal Nicotine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Carboplatin + Sodium Thiosulfate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
loxapine + midazolam - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Escitalopram - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Lithium - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Buspirone - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Memantine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Methylphenidate ER - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SPN-810 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Other Psychiatric Disorders Therapeutics – Drug Profile Updates 41
Other Psychiatric Disorders Therapeutics – Discontinued Products 44
Other Psychiatric Disorders Therapeutics - Dormant Products 45
Other Psychiatric Disorders – Product Development Milestones 46
Featured News & Press Releases 46
Jun 23, 2011: Neurocrine Biosciences Announces Notice Of Allowance For Composition Of Matter Patent On VMAT2 Inhibitor 46
Jun 17, 2011: Ortho-McNeil-Janssen Pharmaceuticals Voluntarily Recalls One Lot Of RISPERDAL Tablets And One Lot Of Risperidone Tablets 46
May 25, 2011: AMRI To Receive Milestone Payment From BMS For Initiation Of Phase II Study 47
Nov 16, 2010: Alkermes Presents Preclinical Data On ALKS 33 For Multiple Disease Indications At Annual Meeting Of Society For Neuroscience 48
Feb 24, 2010: Corcept Initiates Dosing In Phase I Study Of Selective Cortisol Receptor Antagonist 48
Oct 07, 2009: AVANIR Pharmaceuticals Announces Receipt Of Notice Of Allowance Of New US Patent On Zenvia 49
Jul 06, 2009: AVANIR Completes Enrollment Of Zenvia Open Label Extension Study 50
Oct 06, 2006: Johnson's Risperdal Approved For The treatment Of Irritability Associated with Autistic Disorder 51
Apr 28, 2005: SkyePharma and GlaxoSmithKline reach agreement on payment of royalties for Paxil CR. 51
Oct 01, 2004: IVAX Receives Final Approval on Fluoxetine Tablets and Capsules. 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Number of Products Under Development for Other Psychiatric Disorders, H2 2012 8
Products under Development for Other Psychiatric Disorders – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Corcept Therapeutics Incorporated, H2 2012 18
Supernus Pharmaceuticals, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Other Psychiatric Disorders Therapeutics – Drug Profile Updates 41
Other Psychiatric Disorders Therapeutics – Discontinued Products 44
Other Psychiatric Disorders Therapeutics – Dormant Products 45

List of Figures
Number of Products under Development for Other Psychiatric Disorders, H2 2012 8
Products under Development for Other Psychiatric Disorders – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25